Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 6;4:60. doi: 10.1038/s41421-018-0060-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a, b Traces showing the effects of pretreating mice with haloperidol (5 mg·kg^-1; Halo) or WAY100635 (5 mg kg^-1; WAY) on Ca²⁺ signals of dopamine neurons in response to cocaine (Coc) and MDMA. Saline (Sal) was infused as control. c The overall effect of haloperidol or WAY100635 pretreatment on the responses of dopamine neurons [n = 7 dopamine mice for each test group; for cocaine administration with pretreatment, F(3, 24) = 40.76, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test; for MDMA administration with pretreatment, F(3, 24) = 39.24, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test]. d ROC analysis measuring the effect of haloperidol and WAY100635 on the inhibitory responses to cocaine or MDMA [the same group size as in (c) for cocaine administration with pretreatment, F(3, 24) = 65.44, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test; for MDMA administration with pretreatment, F(3, 24) = 47.54, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test]. e, f Representative traces of from serotonin neurons showing the effect of pretreating mice with haloperidol or WAY100635 on the responses to cocaine or MDMA. g The overall effect of haloperidol or WAY100635 pretreatment on the responses of serotonin neurons [n = 9 serotonin mice for Sal-Sal and Sal + Cocaine, n = 6 for Halo + Coc, n = 8 for WAY + Coc, F(3, 26) = 24.02, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test; n = 5 for Sal + Sal, Sal-MDMA, Halo + MDMA, and WAY + MDMA, F(3, 16) = 55.60, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test]. h ROC analysis to discriminate among the effects of haloperidol and WAY100635 on cocaine-induced and MDMA-induced inhibition [the same group size as in (c) for cocaine administration with pretreatment, F(3, 28) = 39.52, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test; for MDMA administration with pretreatment, F(3, 16) = 57.62, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test]. Error bars indicate SEM (c, d, g, h). *p < 0.05; **p < 0.01; ***p < 0.001; ns not significant

Fig. 5 — a, b Traces showing the effects of pretreating mice with haloperidol (5 mg·kg^-1; Halo) or WAY100635 (5 mg kg^-1; WAY) on Ca²⁺ signals of dopamine neurons in response to cocaine (Coc) and MDMA. Saline (Sal) was infused as control. c The overall effect of haloperidol or WAY100635 pretreatment on the responses of dopamine neurons [n = 7 dopamine mice for each test group; for cocaine administration with pretreatment, F(3, 24) = 40.76, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test; for MDMA administration with pretreatment, F(3, 24) = 39.24, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test]. d ROC analysis measuring the effect of haloperidol and WAY100635 on the inhibitory responses to cocaine or MDMA [the same group size as in (c) for cocaine administration with pretreatment, F(3, 24) = 65.44, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test; for MDMA administration with pretreatment, F(3, 24) = 47.54, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test]. e, f Representative traces of from serotonin neurons showing the effect of pretreating mice with haloperidol or WAY100635 on the responses to cocaine or MDMA. g The overall effect of haloperidol or WAY100635 pretreatment on the responses of serotonin neurons [n = 9 serotonin mice for Sal-Sal and Sal + Cocaine, n = 6 for Halo + Coc, n = 8 for WAY + Coc, F(3, 26) = 24.02, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test; n = 5 for Sal + Sal, Sal-MDMA, Halo + MDMA, and WAY + MDMA, F(3, 16) = 55.60, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test]. h ROC analysis to discriminate among the effects of haloperidol and WAY100635 on cocaine-induced and MDMA-induced inhibition [the same group size as in (c) for cocaine administration with pretreatment, F(3, 28) = 39.52, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test; for MDMA administration with pretreatment, F(3, 16) = 57.62, p < 0.0001, one-way ANOVA with Tukey’s post-hoc test]. Error bars indicate SEM (c, d, g, h). *p < 0.05; **p < 0.01; ***p < 0.001; ns not significant